Nomi Health’s Post

Thoughts on this? >> #ADA24: Innovent details Phase 3 weight loss data from Lilly-partnered GLP-1 in Chinese patients >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #pharmaceutical #pharma #biotech #healthcare #productmarketing

In the world of healthcare, few recent innovations have caused as much of a stir as the emergent GLP-1 drugs, which have proven to have a material impact on weight loss. In this new episode Moz Afzal is joined by New Capital Michael Clulow, CFA and Chelsea Wiater to talk through what GLP-1s are, how they work and the potentially far reaching impacts they may have on the consumer staples and healthcare industries. https://lnkd.in/eNSvAC6R

New Case Study Alert: Raise your hand if you’ve accidentally left a door open in the lab! 🖐️ Even with a reliable, real-time monitoring system in place, relying solely on physical presence may not guarantee that you’ll catch every issue. The customer was on-site and unaware of the situation when SafetyNet called. Find out how #SafetyNetSavesTheDay once again! https://lnkd.in/g4X-MhXA #Pharma #LifeScience #EnvironmentalMonitoring

Learn how advanced #IRT settings that enable the management of pooled medication across #ClinicalTrials can reduce supply management oversight and drug management costs. Read the blog. https://lnkd.in/gWAhaVyp #RTSM #Randomization #TrialSupplyManagement #ChooseCalyx

WHAT'S AHEAD FOR THE INFLATION REDUCTION ACT IN 2024? 2024 will be a crucial year for the Inflation Reduction Act, as CMS will finalize prices negotiated for the first 10 Medicare Part D drugs. Our new POV helps #pharma and #biotech #marketaccess teams prepare for the next phase of the landmark legislation, featuring the latest analysis and insights from our team. Read the POV:

Health Advances explores the development, commercial, and regulatory tradeoffs in developing #MDD drugs as monotherapies or adjuncts in our latest blog. Read here: https://bit.ly/4duK0zK #mentalhealth Michael Davitian, Noah Rudisill

On April 30, CEO LeAnn Boyd will join national healthcare leaders in a panel discussion of GLP-1s and their impact on the self-funded employer market. The session, How a Side Effect Turned into a Selling Point for Pharma, is part of the HPI Innovations Self-Funding Conference in Boston. As the first PBM to collaborate with Noom for Work, Liviniti has expertise not only in GLP-1s but in flexible options that support employees on their weight-loss journeys – whether or not their benefit plans extend coverage for this popular drug class. Read more about this panel discussion covering the health and cost impact of drugs such as Wegovy, Ozempic and others: https://lnkd.in/gd9fVY4V #Liviniti #HPI #GLP1s

The choice adjunct vs. monotherapy studies in #MDD is an important decision for drug developers seeking to advance treatments in this important indication. In this blog, we explore the implications of each path.

The GLP-1 battle keeps flaring. With Ozempic, Wegovy, Munjaro, and other drugs falling off insurer and PBM formularies, compounded by the extreme costs (up to $16,000 per year), the market once again proves it will find a way. "Direct-to-consumer pharmaceutical startup Hims & Hers Health said it is selling injectable GLP-1 weight loss drugs for a fraction of the cost of brand-name competitors such as Wegovy and Ozempic. Following the announcement, shares of the telehealth company soared more than 30% Monday. Hims & Hers will provide patients with compounded GLP-1 drugs that start at $199 a month, or about 85% less than brand-name versions like Ozempic and Wegovy. The injectables use the same active ingredients as the branded versions, which currently are in short supply in some doses. Shares of Hims & Hers soared $4.21, or 29%, to $18.79 in Monday afternoon trading. Hims & Hers Health's may also beat out competitors on another key metric: availability. https://lnkd.in/gGdky6q6 #GLP-1 #T2D #Obesity #PBMs #HealthInsurance

Learn how advanced #IRT settings that enable the management of pooled medication across #ClinicalTrials can reduce supply management oversight and drug management costs. Read the blog. https://lnkd.in/g8X4JaYT #RTSM #Randomization #TrialSupplyManagement #ChooseCalyx